These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22548951)

  • 21. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
    Rabasa-Lhoret R; Garon J; Langelier H; Poisson D; Chiasson JL
    Diabetes Care; 1999 May; 22(5):667-73. PubMed ID: 10332663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
    Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
    Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (Insulin Glargine BS Injection "Lilly") and glargine U-300 (Lantus XR): a randomized controlled study.
    Hasebe M; Satoh S; Ito K; Tamura H; Terauchi Y
    Endocr J; 2023 Aug; 70(8):777-786. PubMed ID: 37164694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rate of Change of Premeal Glucose Measured by Continuous Glucose Monitoring Predicts Postmeal Glycemic Excursions in Patients With Type 1 Diabetes: Implications for Therapy.
    Majithia AR; Wiltschko AB; Zheng H; Walford GA; Nathan DM
    J Diabetes Sci Technol; 2018 Jan; 12(1):76-82. PubMed ID: 28868899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.
    Shimoda S; Okubo M; Koga K; Sekigami T; Kawashima J; Kukidome D; Igata M; Ishii N; Shimakawa A; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2015; 62(2):209-16. PubMed ID: 25392020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
    Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
    Umpierrez GE; Gianchandani R; Smiley D; Jacobs S; Wesorick DH; Newton C; Farrokhi F; Peng L; Reyes D; Lathkar-Pradhan S; Pasquel F
    Diabetes Care; 2013 Nov; 36(11):3430-5. PubMed ID: 23877988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can Fasting Glucose Levels or Post-Breakfast Glucose Fluctuations Predict the Occurrence of Nocturnal Asymptomatic Hypoglycemia in Type 1 Diabetic Patients Receiving Basal-Bolus Insulin Therapy with Long-Acting Insulin?
    Mitsuishi S; Nishimura R; Ando K; Tsujino D; Utsunomiya K
    PLoS One; 2015; 10(12):e0144041. PubMed ID: 26625003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
    Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
    Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
    Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
    Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system.
    Jones SM; Quarry JL; Caldwell-McMillan M; Mauger DT; Gabbay RA
    Diabetes Technol Ther; 2005 Apr; 7(2):233-40. PubMed ID: 15857224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
    Rosenstock J; Bergenstal RM; Blevins TC; Morrow LA; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
    Diabetes Care; 2013 Mar; 36(3):522-8. PubMed ID: 23193209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
    Porksen NK; Linnebjerg H; Lam ECQ; Garhyan P; Pachori A; Pratley RE; Smith SR
    Diabetes Obes Metab; 2018 May; 20(5):1193-1201. PubMed ID: 29316143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.